Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is produced ...

AstraZeneca is making another go at developing a medicine like Ozempic. The U.K. pharma giant purchased licensing rights to a candidate in early-stage clinical trials. But that drug will need ...

AstraZeneca is the main vaccine offered in Australia but people increasingly don't want it Australian doctors have reported a surge in the number of people cancelling their vaccine appointments ...

Nov 14 (Reuters) - Drugmaker AstraZeneca (AZN.L) said on Tuesday its cancer drug Imfinzi given along with chemoradiotherapy (CRT) failed to meet its main goal in a late-stage trial to treat ...

AstraZeneca has agreed to pay up to $2 billion for an experimental pill used to treat obesity and type 2 diabetes—the latest pharmaceutical firm to bet on treatment similar to popular weight ...

AstraZeneca CEO Pascal Soriot discusses Q3 earnings, oncology revenue, gene therapy treatments, what's to come for the company and the U.S. supply chain. Donald Trump Being Kicked off 2024 Ballot ...

AstraZeneca raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines despite a lower third-quarter profit that missed forecasts after booking a tax ...

Roula Khalaf, Editor of the FT, selects her favourite stories in this weekly newsletter. AstraZeneca is to enter the race for a weight loss pill, working on a next-generation class of drugs that ...

Shares of AstraZeneca rose as much as 4.2% in early trade after the company raised its full-year guidance for core earnings per share and total revenue excluding Covid-19 medicines after beating ...

Proactive financial news and online broadcast teams provide fast, accessible, informative and actionable business and finance news content to a global investment audience. All our content is ...